Chong Kun Dang Holdings Corp. (001630.KS)
KRW 45500.0
(2.13%)
KRW 45500.0
(2.13%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 350.71 Billion KRW | -17.95% |
| 2022 | 432.06 Billion KRW | 6.16% |
| 2021 | 406.99 Billion KRW | 25.37% |
| 2020 | 324.63 Billion KRW | 33.6% |
| 2019 | 242.98 Billion KRW | 62.69% |
| 2018 | 149.35 Billion KRW | 20.93% |
| 2017 | 123.5 Billion KRW | 55.4% |
| 2016 | 79.47 Billion KRW | 89.31% |
| 2015 | 41.98 Billion KRW | 51.57% |
| 2014 | 27.69 Billion KRW | -86.32% |
| 2013 | 202.41 Billion KRW | -8.4% |
| 2012 | 220.96 Billion KRW | -0.0% |
| 2011 | 220.97 Billion KRW | 0.76% |
| 2010 | 219.3 Billion KRW | 15.67% |
| 2009 | 189.59 Billion KRW | 21.2% |
| 2008 | 156.43 Billion KRW | 16.38% |
| 2007 | 134.41 Billion KRW | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | -102.91 Billion KRW | -209.59% |
| 2024 Q2 | 101.67 Billion KRW | 198.18% |
| 2023 Q3 | -92.15 Billion KRW | -197.27% |
| 2023 Q2 | 94.74 Billion KRW | 15.22% |
| 2023 Q1 | 82.22 Billion KRW | -19.89% |
| 2023 Q4 | 93.9 Billion KRW | 201.9% |
| 2023 FY | 354.49 Billion KRW | -17.95% |
| 2022 Q4 | 102.64 Billion KRW | -9.0% |
| 2022 Q1 | 109.96 Billion KRW | 8.89% |
| 2022 FY | 432.06 Billion KRW | 6.16% |
| 2022 Q2 | 106.66 Billion KRW | -3.0% |
| 2022 Q3 | 112.78 Billion KRW | 5.74% |
| 2021 Q2 | 107.43 Billion KRW | 6.07% |
| 2021 FY | 406.99 Billion KRW | 25.37% |
| 2021 Q4 | 100.99 Billion KRW | 3.81% |
| 2021 Q1 | 101.28 Billion KRW | 0.6% |
| 2021 Q3 | 97.28 Billion KRW | -9.44% |
| 2020 Q4 | 100.68 Billion KRW | 22.77% |
| 2020 Q2 | 72.42 Billion KRW | 4.2% |
| 2020 Q1 | 69.5 Billion KRW | -1.03% |
| 2020 FY | 324.63 Billion KRW | 33.6% |
| 2020 Q3 | 82.01 Billion KRW | 13.23% |
| 2019 Q4 | 70.22 Billion KRW | 22.77% |
| 2019 FY | 242.98 Billion KRW | 62.69% |
| 2019 Q1 | 56.48 Billion KRW | 30.74% |
| 2019 Q2 | 59.07 Billion KRW | 4.59% |
| 2019 Q3 | 57.2 Billion KRW | -3.16% |
| 2018 Q1 | 34.87 Billion KRW | 10.76% |
| 2018 Q2 | 34.1 Billion KRW | -2.2% |
| 2018 Q4 | 43.2 Billion KRW | 16.2% |
| 2018 Q3 | 37.17 Billion KRW | 9.01% |
| 2018 FY | 149.35 Billion KRW | 20.93% |
| 2017 Q4 | 31.48 Billion KRW | -6.44% |
| 2017 Q2 | 31.29 Billion KRW | 15.55% |
| 2017 Q1 | 27.08 Billion KRW | 5.17% |
| 2017 FY | 123.5 Billion KRW | 55.4% |
| 2017 Q3 | 33.65 Billion KRW | 7.54% |
| 2016 Q3 | 21 Billion KRW | 21.03% |
| 2016 Q1 | 15.36 Billion KRW | 9.41% |
| 2016 Q4 | 25.75 Billion KRW | 22.61% |
| 2016 FY | 79.47 Billion KRW | 89.31% |
| 2016 Q2 | 17.35 Billion KRW | 12.97% |
| 2015 Q1 | 6.81 Billion KRW | -4.48% |
| 2015 Q4 | 14.03 Billion KRW | 3.04% |
| 2015 Q3 | 13.62 Billion KRW | 81.7% |
| 2015 Q2 | 7.49 Billion KRW | 9.96% |
| 2015 FY | 41.98 Billion KRW | 51.57% |
| 2014 Q1 | 6.2 Billion KRW | -79.79% |
| 2014 Q4 | 7.13 Billion KRW | -15.06% |
| 2014 FY | 27.69 Billion KRW | -86.32% |
| 2014 Q3 | 8.4 Billion KRW | 41.36% |
| 2014 Q2 | 5.94 Billion KRW | -4.22% |
| 2013 Q2 | 59.41 Billion KRW | 6.14% |
| 2013 Q3 | 56.65 Billion KRW | -4.63% |
| 2013 Q4 | 30.71 Billion KRW | -45.78% |
| 2013 FY | 202.41 Billion KRW | -8.4% |
| 2013 Q1 | 55.97 Billion KRW | -7.63% |
| 2012 Q1 | 45.67 Billion KRW | 0.0% |
| 2012 Q2 | 53.78 Billion KRW | 17.77% |
| 2012 Q3 | 56.72 Billion KRW | 5.46% |
| 2012 Q4 | 60.59 Billion KRW | 6.83% |
| 2012 FY | 220.96 Billion KRW | -0.0% |
| 2011 Q2 | 49.01 Billion KRW | 3.83% |
| 2011 FY | 220.97 Billion KRW | 0.76% |
| 2011 Q1 | 47.21 Billion KRW | 0.0% |
| 2011 Q3 | 46.37 Billion KRW | -5.4% |
| 2011 Q4 | - KRW | -100.0% |
| 2010 Q3 | 47.15 Billion KRW | -7.32% |
| 2010 Q4 | - KRW | -100.0% |
| 2010 FY | 219.3 Billion KRW | 15.67% |
| 2010 Q2 | 50.88 Billion KRW | 6.4% |
| 2010 Q1 | 47.82 Billion KRW | 0.0% |
| 2009 Q3 | 41.54 Billion KRW | -6.33% |
| 2009 Q4 | - KRW | -100.0% |
| 2009 Q2 | 44.35 Billion KRW | 10.38% |
| 2009 Q1 | 40.18 Billion KRW | 0.0% |
| 2009 FY | 189.59 Billion KRW | 21.2% |
| 2008 Q1 | 32.34 Billion KRW | 0.0% |
| 2008 Q3 | 35.54 Billion KRW | 0.45% |
| 2008 Q4 | - KRW | -100.0% |
| 2008 Q2 | 35.38 Billion KRW | 9.41% |
| 2008 FY | 156.43 Billion KRW | 16.38% |
| 2007 Q1 | 28.32 Billion KRW | 0.0% |
| 2007 Q4 | - KRW | -100.0% |
| 2007 Q3 | 32.66 Billion KRW | 3.47% |
| 2007 Q2 | 31.57 Billion KRW | 11.46% |
| 2007 FY | 134.41 Billion KRW | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Dongwha Pharm.Co.,Ltd | 165.11 Billion KRW | -112.409% |
| Yuhan Corporation | 489.94 Billion KRW | 28.417% |
| Yuhan Corporation | 489.94 Billion KRW | 28.417% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -642.195% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -642.195% |
| Yuyu Pharma, Inc. | 47.25 Billion KRW | -642.195% |
| Ildong Holdings Co., Ltd. | 278.43 Billion KRW | -25.958% |
| Samil Pharmaceutical Co.,Ltd | 65.75 Billion KRW | -433.397% |
| Dong-A Socio Holdings Co., Ltd. | 297.99 Billion KRW | -17.693% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -46.798% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -46.798% |
| JW Pharmaceutical Corporation | 238.91 Billion KRW | -46.798% |
| SAMSUNG PHARM. Co., LTD. | 41.78 Billion KRW | -739.245% |
| Dong Sung Bio Pharm.Co.,Ltd. | 40.05 Billion KRW | -775.627% |
| HANDOK Inc. | 153.76 Billion KRW | -128.081% |
| Jeil Pharma Holdings Inc | 193.66 Billion KRW | -81.095% |
| Kukje Pharma Co., Ltd. | 69.21 Billion KRW | -406.716% |
| Bukwang Pharmaceutical Co., Ltd. | 87.54 Billion KRW | -300.626% |
| Aprogen pharmaceuticals,Inc. | 58.64 Billion KRW | -498.04% |
| Ilsung Pharmaceuticals Co., Ltd. | 42.47 Billion KRW | -725.763% |
| Daewon Pharmaceutical Co., Ltd. | 221.99 Billion KRW | -57.981% |
| Yungjin Pharm. Co., Ltd. | 69.46 Billion KRW | -404.856% |
| Boryung Corporation | 285.16 Billion KRW | -22.988% |
| Hyundai Pharmaceutical Co., Ltd. | 68.31 Billion KRW | -413.411% |
| Samjin Pharmaceuticals Co., Ltd. | 126.39 Billion KRW | -177.481% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -101.389% |
| Ilyang Pharmaceutical Co.,Ltd | 174.14 Billion KRW | -101.389% |
| Suheung Co., Ltd. | 56.03 Billion KRW | -525.92% |
| Kwang Dong Pharmaceutical Co., Ltd. | 249.12 Billion KRW | -40.781% |
| Hanall Biopharma Co.,Ltd | 71.98 Billion KRW | -387.218% |
| Whan In Pharm Co.,Ltd. | 66.41 Billion KRW | -428.049% |
| MYUNGMOON Pharm co.,Ltd | 93.55 Billion KRW | -274.891% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -174.706% |
| Shin Poong Pharm.Co.,Ltd. | 127.66 Billion KRW | -174.706% |
| Korea United Pharm Inc. | 118.21 Billion KRW | -196.679% |
| CKD Bio Corp. | 25.19 Billion KRW | -1291.965% |
| Daewoong pharmaceutical Co.,Ltd | 560.43 Billion KRW | 37.42% |
| JW Holdings Corporation | 301.25 Billion KRW | -16.418% |
| REYON Pharmaceutical Co., Ltd. | 75.04 Billion KRW | -367.315% |
| Hanmi Pharm. Co., Ltd. | 610.97 Billion KRW | 42.597% |
| Dong-A ST Co., Ltd. | 306.95 Billion KRW | -14.256% |
| Chong Kun Dang Pharmaceutical Corp. | 408.65 Billion KRW | 14.178% |
| JW Lifescience Corporation | 20.26 Billion KRW | -1630.942% |
| Ildong Pharmaceutical Co., Ltd. | 260.95 Billion KRW | -34.397% |
| Jeil Pharmaceutical Co.,Ltd | 174.92 Billion KRW | -100.494% |
| Hana Pharm Co., Ltd. | 114.72 Billion KRW | -205.702% |